Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs SoFi Technologies Inc (SOFI) Price & Performance

AbbVie IncTrade
SoFi Technologies IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs SoFi Technologies Inc — how do they compare? AbbVie Inc trades at $249.99 (market cap $438.19B), while SoFi Technologies Inc trades at $18 (market cap $23.40B). The key difference: AbbVie Inc is far larger — about 18.7× SoFi Technologies Inc's market cap, and AbbVie Inc pays a 2.79% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.

ABBVSOFI
Market Cap
$438.19B$23.40B
Sector
HealthFinancials
52-Week High
$263.58$32.21
52-Week Low
$197.38$15.15
Enterprise Value
$502.45B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

SoFi Technologies Inc

SoFi Technologies (SOFI) trades at $18.38, up 1.55% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75–$4.85 billion, though EBITDA and earnings outlooks were maintained. The stock's valuation shows a P/E of 37.51 and P/S of 5.73, reflecting growth expectations amid profitability improvements.

The outlook for SOFI is cautiously optimistic, driven by robust member growth, cross-selling success, and a diversified revenue stream. Key opportunities include continued execution on the 'everything app' strategy and potential upside to the $19.50 consensus price target. Risks involve reliance on lending growth, pressure on Technology Platform margins, and sensitivity to Federal Reserve rate decisions. Investors should weigh strong fundamentals against high valuation multiples and competitive fintech pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About SoFi Technologies Inc

SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.

Read more on SOFI